{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:12:37Z","timestamp":1760242357371,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T00:00:00Z","timestamp":1494288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of sofosbuvir plus weight-based ribavirin daily. This treatment led to higher sustained virologic response at 12-weeks post-treatment (SVR12) rates in both treatment-na\u00efve and treatment-experienced patients. The efficacy of this treatment in compensated cirrhotics was the same as that in patients with chronic hepatitis. HCV GT-2a infection and lower estimated glomerular filtration rates (eGFR) tended to be associated with SVR12. Of 114 patients, 113 completed the combination of sofosbuvir plus ribavirin for 12 weeks. Seven patients without SVR12 did not have HCV NS5B-S282 mutations. The overall SVR12 rate was 90.4% (103 of 114). More effective therapeutic options with less adverse events are desired to achieve higher SVR rates in HCV GT-2 Japanese patients.<\/jats:p>","DOI":"10.3390\/biology6020030","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T11:50:48Z","timestamp":1494330648000},"page":"30","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9565-4669","authenticated-orcid":false,"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Haga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Tawada","sequence":"additional","affiliation":[{"name":"Safety and Health Organization, Chiba University, 1-33 Yayoicho, Inage-ku, Chiba 263-8522, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Ooka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Imazeki","sequence":"additional","affiliation":[{"name":"Safety and Health Organization, Chiba University, 1-33 Yayoicho, Inage-ku, Chiba 263-8522, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yokosuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"34S","DOI":"10.1002\/hep.510260706","article-title":"Hepatitis C and hepatocellular carcinoma","volume":"26","year":"1997","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.1073\/pnas.87.17.6547","article-title":"Hepatitis C virus infection is associated with the development of hepatocellular carcinoma","volume":"87","author":"Saito","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12072-010-9193-3","article-title":"New antiviral therapies for chronic hepatitis C","volume":"4","author":"Kanda","year":"2010","journal-title":"Hepatol. Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12072-016-9749-y","article-title":"Interferon-free treatment for HCV-infected patients with decompensated cirrhosis","volume":"11","author":"Kanda","year":"2017","journal-title":"Hepatol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s12072-015-9630-4","article-title":"Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries","volume":"9","author":"Omata","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s10620-011-1750-7","article-title":"Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2","volume":"56","author":"Kanda","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7150\/ijms.5358","article-title":"Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy","volume":"10","author":"Kanda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2893.2004.00531.x","article-title":"Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: Ribavirin induces mutagenesis in HCV RNA","volume":"11","author":"Kanda","year":"2004","journal-title":"J. Viral Hepat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jvh.12312","article-title":"Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: An open-label, phase 3 trial","volume":"21","author":"Omata","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Etoh, R., Imazeki, F., Kurihara, T., Fukai, K., Fujiwara, K., Arai, M., Kanda, T., Mikata, R., Yonemitsu, Y., and Yokosuka, O. (2011). Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response. BMC Res. Notes, 4.","DOI":"10.1186\/1756-0500-4-316"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/hep.24512","article-title":"The assessment of serum hepatitis C virus RNA 12 weeks after the end of treatment using TaqMan polymerase chain reaction is less relevant than after 24 weeks for predicting sustained virological response","volume":"54","author":"Kanda","year":"2011","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2013.02.039","article-title":"Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies","volume":"144","author":"Chen","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7150\/ijms.14953","article-title":"Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3\/4A Protease Inhibitors with Peginterferon plus Ribavirin","volume":"13","author":"Kanda","year":"2016","journal-title":"Int. J. Med. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ohta, Y., Kanda, T., Katsuno, T., Yasui, S., Haga, Y., Sasaki, R., Nakamura, M., Wu, S., Nakamoto, S., and Arai, M. (2016). Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: A case report. BMC Gastroenterol.","DOI":"10.1186\/s12876-016-0480-x"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000445374","article-title":"Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation","volume":"10","author":"Sasaki","year":"2016","journal-title":"Case Rep. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000447423","article-title":"Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin","volume":"10","author":"Sasaki","year":"2016","journal-title":"Case Rep. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Win, N.N., Nakamoto, S., Kanda, T., Takahashi, H., Takahashi-Nakaguchi, A., Yasui, S., Nakamura, M., Wu, S., Imazeki, F., and Mikami, S. (2017). Discrepancy between Hepatitis C Virus Genotypes and NS4-Based Serotypes: Association with Their Subgenomic Sequences. Int. J. Mol. Sci.","DOI":"10.3390\/ijms18010172"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3851\/IMP2426","article-title":"Antiviral resistance and direct-acting antiviral agents for HCV","volume":"17","author":"Aloia","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2014.12.037","article-title":"Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations","volume":"477","author":"Ji","year":"2015","journal-title":"Virology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.28782","article-title":"Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study","volume":"64","author":"Tapper","year":"2016","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.antiviral.2016.10.012","article-title":"Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis","volume":"136","author":"Ogawa","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Morio, K., Imamura, M., Kawakami, Y., Nakahara, T., Nagaoki, Y., Kawaoka, T., Tsuge, M., Hiramatsu, A., Aikata, H., and Hayes, C.N. (2016). ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. J. Gastroenterol.","DOI":"10.1007\/s00535-016-1279-9"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e6128","DOI":"10.1097\/MD.0000000000006128","article-title":"Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease","volume":"96","author":"Chang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/v4081264","article-title":"Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin","volume":"4","author":"Miyamura","year":"2012","journal-title":"Viruses"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1159\/000448823","article-title":"Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2","volume":"34","author":"Sugimoto","year":"2016","journal-title":"Dig. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kozuka, R., Hai, H., Teranishi, Y., Motoyama, H., Kawamura, E., Hagihara, A., Uchida-Kobayashi, S., Morikawa, H., Enomoto, M., and Murakami, Y. (2017). ITPA polymorphism correlates with the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy. J. Gastroenterol. Hepatol.","DOI":"10.1111\/jgh.13743"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10930-013-9462-9","article-title":"Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes","volume":"32","author":"Elfiky","year":"2013","journal-title":"Protein J."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gane, E.J., Hyland, R.H., Yang, Y., Svarovskaia, E., Stamm, L.M., Brainard, D.M., McHutchison, J.G., and Stedman, C.A. (2017). Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection. Gastroenterology.","DOI":"10.1053\/j.gastro.2017.01.017"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOT.0000000000000198","article-title":"New hepatitis C virus therapies: Drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease","volume":"20","author":"Kwo","year":"2015","journal-title":"Curr. Opin. Organ Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S2468-1253(16)30204-7","article-title":"Hepatitis C treatment and liver cancer recurrence: Cause for concern?","volume":"2","author":"Debes","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/cid\/civ474","article-title":"Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir","volume":"61","author":"Collins","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/hepr.12578","article-title":"Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus\/hepatitis C virus co-infection","volume":"46","author":"Takayama","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","article-title":"Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): A multicentre, open-label, non-randomised, phase 3 study","volume":"385","author":"Molina","year":"2015","journal-title":"Lancet"}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/6\/2\/30\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:35:09Z","timestamp":1760207709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/6\/2\/30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,9]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["biology6020030"],"URL":"https:\/\/doi.org\/10.3390\/biology6020030","relation":{},"ISSN":["2079-7737"],"issn-type":[{"type":"electronic","value":"2079-7737"}],"subject":[],"published":{"date-parts":[[2017,5,9]]}}}